Bayer launches cell and gene therapy platform
Goal is to enable support of partners through its expertise and resources
Germany-based Bayer AG recently launched a cell and gene therapy (C>) platform within its pharmaceuticals division.
Stefan Oelrich, a member of the company’s Board of Management and president of the pharma division, says that with the rapid growth of C>, Bayer believes the time is now to competitively establish itself in this field. A challenge that Bayer is ready for, he says.
“This is a defining moment for Bayer. Cell and gene therapies are leading innovation in healthcare, and it is our goal to be at the forefront of this revolution in science," Oelrich stated. "This will complement our existing C> pipeline, which already includes five advanced assets with at least three investigational new drugs annually for the next years.“
As part of the pharma division, the C> platform will merge several functions, providing support across the entire value chain for the R&D of C>s. This includes expertise in research and preclinical development, CMC (chemistry, manufacturing and controls), clinical development, commercial, strategy implementation and project management.
Bayer focuses on selected areas of C>, such as stem cell therapies, gene augmentation, gene editing and allogeneic cell therapies. In 2019, it acquired BlueRock Therapeutics, and a deal with Asklepios Biopharmaceutical closed on Dec. 1 of this year. These initial partners are starting to enroll in Bayer’s C> platform.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
